TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of the Use of Mild Hypothermia in Out-of-hospital Cardiac Arrest Using a Rapid Infusion of 2 Liters of Cold Normal Saline
Brief Summary: The overall goal of this study is to determine whether initiating hypothermia in cardiac arrest patients as soon as possible in the field results in a greater proportion of patients who survive to hospital discharge compared to standard prehospital/field care.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Device: Prehospital intra-nasal cooling with RhinoChill | Intervention Type: DEVICE; Name: Prehospital intra-nasal cooling with RhinoChill; Assigned to Arm(s): Intervention
B: Arm Label: Target Temperature 33°C; Type: EXPERIMENTAL; Interventions: Procedure: Target Temperature 33°C | Arm Label: Target Temperature 36°C; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Target temperature 36°C | Intervention Type: PROCEDURE; Name: Target temperature 36°C; Assigned to Arm(s): Target Temperature 36°C | Intervention Type: PROCEDURE; Name: Target Temperature 33°C; Assigned to Arm(s): Target Temperature 33°C
C: Arm Label: control treatment; Type: NO_INTERVENTION; Interventions: Other: Rapid infusion of 2 liters of 4oC normal saline, Drug: Rapid infusion of cold normal saline | Intervention Type: OTHER; Name: Rapid infusion of 2 liters of 4oC normal saline; Assigned to Arm(s): control treatment | Intervention Type: DRUG; Name: Rapid infusion of cold normal saline; Assigned to Arm(s): control treatment
D: Arm Label: RhinoChill; Type: EXPERIMENTAL; Interventions: Device: RhinoChill | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: DEVICE; Name: RhinoChill; Assigned to Arm(s): RhinoChill | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Behavioral Intervention Trial to Reduce Transmission Risks and Improve HCV Treatment Access Among HCV-infected Injection Drug Users
Brief Summary: The purpose of this study is to determine whether a six-session, small group behavioral intervention based on "peer-volunteer activism" is effective in (1) decreasing distributive sharing of syringes and other injection paraphernalia and (2) increasing utilization of HCV-related healthcare services among HCV-infected injection drug users


Options:
A: Intervention Type: BEHAVIORAL; Name: Peer Mentoring Intervention for HCV-Infected IDUs; Assigned to Arm(s): N/A
B: Arm Label: NCMIT; Type: EXPERIMENTAL; Interventions: Behavioral: NCMIT | Arm Label: SCMIT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SCMIT | Intervention Type: BEHAVIORAL; Name: NCMIT; Assigned to Arm(s): NCMIT | Intervention Type: BEHAVIORAL; Name: SCMIT; Assigned to Arm(s): SCMIT
C: Arm Label: SBIRT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SBIRT | Arm Label: SBIRT+; Type: EXPERIMENTAL; Interventions: Behavioral: SBIRT+ | Intervention Type: BEHAVIORAL; Name: SBIRT; Assigned to Arm(s): SBIRT | Intervention Type: BEHAVIORAL; Name: SBIRT+; Assigned to Arm(s): SBIRT+
D: Arm Label: Control Group: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Motivational Network Interview Recipients; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Network Interview | Intervention Type: BEHAVIORAL; Name: Motivational Network Interview; Assigned to Arm(s): Motivational Network Interview Recipients

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind Study to Evaluate the Safety and Effectiveness of the Exhale® Drug-Eluting Stent in Homogeneous Emphysema Subjects With Severe Hyperinflation
Brief Summary: This is an international clinical research study evaluating the safety and effectiveness of a new procedure called airway bypass. The goal of this research is to see if airway bypass can relieve hyperinflation (overfilling) of the lungs, thereby improving lung function and reducing shortness of breath in patients with severe homogeneous (diffuse) emphysema. "EASE" stands for Exhale Airway Stents for Emphysema.


Options:
A: Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Device: Sham control | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Exhale® Drug-Eluting Stent | Intervention Type: DEVICE; Name: Exhale® Drug-Eluting Stent; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Sham control; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: IBV® Valve System | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Device: IBV® Valve System | Intervention Type: DEVICE; Name: IBV® Valve System; Assigned to Arm(s): 1, 2
C: Arm Label: Lung Volume Reduction Coil (LVRC); Type: EXPERIMENTAL; Interventions: Device: Lung Volume Reduction Coil (LVRC) (PneumRx's) | Intervention Type: DEVICE; Name: Lung Volume Reduction Coil (LVRC) (PneumRx's); Assigned to Arm(s): Lung Volume Reduction Coil (LVRC)
D: Arm Label: BTVA; Type: EXPERIMENTAL; Interventions: Device: BTVA System | Intervention Type: DEVICE; Name: BTVA System; Assigned to Arm(s): BTVA

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind Study to Evaluate the Safety and Effectiveness of the Exhale® Drug-Eluting Stent in Homogeneous Emphysema Subjects With Severe Hyperinflation
Brief Summary: This is an international clinical research study evaluating the safety and effectiveness of a new procedure called airway bypass. The goal of this research is to see if airway bypass can relieve hyperinflation (overfilling) of the lungs, thereby improving lung function and reducing shortness of breath in patients with severe homogeneous (diffuse) emphysema. "EASE" stands for Exhale Airway Stents for Emphysema.


Options:
A: Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Device: Sham control | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Exhale® Drug-Eluting Stent | Intervention Type: DEVICE; Name: Exhale® Drug-Eluting Stent; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Sham control; Assigned to Arm(s): 2
B: Intervention Type: PROCEDURE; Name: Lung volume reduction surgery; Assigned to Arm(s): N/A
C: Arm Label: Lung volume reduction coïl treatment; Type: EXPERIMENTAL; Interventions: Procedure: Lung volume reduction coïl treatment, Other: Regular medical treatment | Arm Label: Regular Medical Treatment; Type: OTHER; Interventions: Other: Regular medical treatment | Intervention Type: PROCEDURE; Name: Lung volume reduction coïl treatment; Assigned to Arm(s): Lung volume reduction coïl treatment | Intervention Type: OTHER; Name: Regular medical treatment; Assigned to Arm(s): Lung volume reduction coïl treatment, Regular Medical Treatment
D: Arm Label: Lung volume reduction surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Lung volume reduction surgery | Arm Label: No lung volume reduction surgery; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Lung volume reduction surgery; Assigned to Arm(s): Lung volume reduction surgery

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of Quadriceps Muscle Electrostimulation Used as an Additional Procedure for Effort Retraining in Patients Suffering From Cystic Fibrosis Associated With Severe Pulmonary Dysfunction
Brief Summary: This is an add-on, randomized, open label, clinical trial that evaluates the use of quadriceps electrostimulation as an additional retraining procedure in patients suffering from cystic fibrosis.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Electrostimulation programme: using a cycloergometer | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual sport activity | Intervention Type: BEHAVIORAL; Name: Electrostimulation programme: using a cycloergometer; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Usual sport activity; Assigned to Arm(s): 2
B: Arm Label: Exercise; Type: OTHER; Interventions: Other: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
C: Arm Label: Sit-to-stand test; Type: EXPERIMENTAL; Interventions: Behavioral: Sit-to-stand test | Arm Label: 6-Minute Walk Test; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 6-Minute Walk Test | Intervention Type: BEHAVIORAL; Name: Sit-to-stand test; Assigned to Arm(s): Sit-to-stand test | Intervention Type: BEHAVIORAL; Name: 6-Minute Walk Test; Assigned to Arm(s): 6-Minute Walk Test
D: Arm Label: Exercise Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise Intervention; Assigned to Arm(s): Exercise Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of Quadriceps Muscle Electrostimulation Used as an Additional Procedure for Effort Retraining in Patients Suffering From Cystic Fibrosis Associated With Severe Pulmonary Dysfunction
Brief Summary: This is an add-on, randomized, open label, clinical trial that evaluates the use of quadriceps electrostimulation as an additional retraining procedure in patients suffering from cystic fibrosis.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Electrostimulation programme: using a cycloergometer | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual sport activity | Intervention Type: BEHAVIORAL; Name: Electrostimulation programme: using a cycloergometer; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Usual sport activity; Assigned to Arm(s): 2
B: Arm Label: 1. Exercise testing and self drainage session; Type: EXPERIMENTAL; Interventions: Procedure: Chest physiotherapy | Arm Label: 2. Chest physiotherapy (CP) session; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Chest physiotherapy | Intervention Type: PROCEDURE; Name: Chest physiotherapy; Assigned to Arm(s): 1. Exercise testing and self drainage session, 2. Chest physiotherapy (CP) session
C: Intervention Type: BEHAVIORAL; Name: Supervised aerobic training; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Supervised strength training; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Unsupervised training; Assigned to Arm(s): N/A
D: Arm Label: Exercise; Type: OTHER; Interventions: Other: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open-Label Study of the Safety and Efficacy of a Low Dose Oral Contraceptive Containing Norethindrone Acetate and Ethinyl Estradiol
Brief Summary: This is a non-comparative study. The primary objective of the study is to assess the efficacy of a low dose oral contraceptive in the prevention of pregnancy. The secondary objectives are to assess the incidence of intracyclic bleeding; and to assess the safety and tolerability of the product.


Options:
A: Arm Label: 1; Type: N/A; Interventions: N/A | Arm Label: 2; Type: N/A; Interventions: N/A
B: Arm Label: study drug; Type: EXPERIMENTAL; Interventions: Drug: Norethindrone acetate/ethinyl estradiol | Intervention Type: DRUG; Name: Norethindrone acetate/ethinyl estradiol; Assigned to Arm(s): study drug
C: Arm Label: Normal Weight group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose formulation, Drug: High dose formulation | Arm Label: Obese group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose formulation, Drug: High dose formulation | Intervention Type: DRUG; Name: Low dose formulation; Assigned to Arm(s): Normal Weight group, Obese group | Intervention Type: DRUG; Name: High dose formulation; Assigned to Arm(s): Normal Weight group, Obese group
D: Arm Label: AG200-15 (cycles 1-13); Type: EXPERIMENTAL; Interventions: Drug: AG200-15 (cycles 1-13) | Arm Label: Lessina crossover to AG200-15; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lessina crossover to AG200-15 | Intervention Type: DRUG; Name: AG200-15 (cycles 1-13); Assigned to Arm(s): AG200-15 (cycles 1-13) | Intervention Type: DRUG; Name: Lessina crossover to AG200-15; Assigned to Arm(s): Lessina crossover to AG200-15

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacist-initiated Intervention Trial in OsteoArthritis (PhIT-OA)
Brief Summary: Osteoarthritis (OA) is a major public health concern. Currently, there are at least 3 million Canadians afflicted with this condition with a 50% increase predicted by 2020. It is estimated that 85% of Canadians are afflicted with OA by age 70. As such, using the current health care structure, it is doubtful that the health system can keep pace with this increasing demand. Alternative health care delivery strategies must be investigated.

The purpose of this study is to assess if a pharmacist-initiated intervention for individuals with knee pain with a high likelihood of knee OA will lead to an improvement in the quality of care for these individuals.

We are hopeful that results of this study will show better management of knee osteoarthritis by a pharmacist-initiated intervention (which means that it is the pharmacist who will start the process for an intervention that includes exercise and an educational program when compared to no intervention. If this is the case, by implementing the proposed intervention program, subjects could be diagnosed earlier, the burden of illness on individuals could be diminished through an appropriate intervention program, and economic savings could be embraced.

Hypothesis: Community pharmacists can identify patients with likely knee OA and initiate a multidisciplinary intervention that will improve quality of care and outcomes.


Options:
A: Arm Label: experimental; Type: EXPERIMENTAL; Interventions: Other: intensive implementation programme | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: control | Intervention Type: OTHER; Name: intensive implementation programme; Assigned to Arm(s): experimental | Intervention Type: OTHER; Name: control; Assigned to Arm(s): control
B: Arm Label: 1; Type: N/A; Interventions: Other: 1 | Arm Label: 2; Type: N/A; Interventions: Other: 2 | Intervention Type: OTHER; Name: 1; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: 2; Assigned to Arm(s): 2
C: Arm Label: TEAM Care; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmacy TEAM monitoring and counseling | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Pharmacy TEAM monitoring and counseling; Assigned to Arm(s): TEAM Care
D: Arm Label: Health service provision; Type: EXPERIMENTAL; Interventions: Procedure: Pharmacist-Initiated Intervention in OsteoArthritis (PhIT-OA) | Intervention Type: PROCEDURE; Name: Pharmacist-Initiated Intervention in OsteoArthritis (PhIT-OA); Assigned to Arm(s): Health service provision

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacist-initiated Intervention Trial in OsteoArthritis (PhIT-OA)
Brief Summary: Osteoarthritis (OA) is a major public health concern. Currently, there are at least 3 million Canadians afflicted with this condition with a 50% increase predicted by 2020. It is estimated that 85% of Canadians are afflicted with OA by age 70. As such, using the current health care structure, it is doubtful that the health system can keep pace with this increasing demand. Alternative health care delivery strategies must be investigated.

The purpose of this study is to assess if a pharmacist-initiated intervention for individuals with knee pain with a high likelihood of knee OA will lead to an improvement in the quality of care for these individuals.

We are hopeful that results of this study will show better management of knee osteoarthritis by a pharmacist-initiated intervention (which means that it is the pharmacist who will start the process for an intervention that includes exercise and an educational program when compared to no intervention. If this is the case, by implementing the proposed intervention program, subjects could be diagnosed earlier, the burden of illness on individuals could be diminished through an appropriate intervention program, and economic savings could be embraced.

Hypothesis: Community pharmacists can identify patients with likely knee OA and initiate a multidisciplinary intervention that will improve quality of care and outcomes.


Options:
A: Arm Label: 1; Type: N/A; Interventions: Other: 1 | Arm Label: 2; Type: N/A; Interventions: Other: 2 | Intervention Type: OTHER; Name: 1; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: 2; Assigned to Arm(s): 2
B: Arm Label: Health service provision; Type: EXPERIMENTAL; Interventions: Procedure: Pharmacist-Initiated Intervention in OsteoArthritis (PhIT-OA) | Intervention Type: PROCEDURE; Name: Pharmacist-Initiated Intervention in OsteoArthritis (PhIT-OA); Assigned to Arm(s): Health service provision
C: Arm Label: 24 Month PPCM BP; Type: EXPERIMENTAL; Interventions: Other: 24 Month PPCM BP | Arm Label: 9 Month PPCM BP; Type: EXPERIMENTAL; Interventions: Other: 9 Month PPCM BP | Arm Label: PPCM Asthma; Type: SHAM_COMPARATOR; Interventions: Other: PPCM Asthma | Arm Label: BP Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: PPCM Asthma; Assigned to Arm(s): PPCM Asthma | Intervention Type: OTHER; Name: 24 Month PPCM BP; Assigned to Arm(s): 24 Month PPCM BP | Intervention Type: OTHER; Name: 9 Month PPCM BP; Assigned to Arm(s): 9 Month PPCM BP
D: Arm Label: PHCVRS intervention; Type: EXPERIMENTAL; Interventions: Other: PHCVRS Intervention, Other: Personal Health Record | Arm Label: Usual care/Personal Health Record; Type: OTHER; Interventions: Other: Personal Health Record | Intervention Type: OTHER; Name: PHCVRS Intervention; Assigned to Arm(s): PHCVRS intervention | Intervention Type: OTHER; Name: Personal Health Record; Assigned to Arm(s): PHCVRS intervention, Usual care/Personal Health Record

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inhibition and Patient Outcomes]
Brief Summary: Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack. ACS is usually caused by the formation of a blood clot in an artery that partially or totally blocks the blood supply to a portion of the heart muscle. Ticagrelor will be compared with clopidogrel to determine which drug, when either is used in conjunction with aspirin, is better at reducing deaths from vascular causes, future heart attacks and/or strokes in patients with ACS.


Options:
A: Arm Label: Aspirin; Type: EXPERIMENTAL; Interventions: Drug: Aspirin | Arm Label: Aspirin,Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin,Clopidogrel | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Aspirin | Intervention Type: DRUG; Name: Aspirin,Clopidogrel; Assigned to Arm(s): Aspirin,Clopidogrel
B: Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Ticagrelor | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel
C: Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin monotherapy | Arm Label: Aspirin,Clopidogrel; Type: EXPERIMENTAL; Interventions: Drug: Aspirin,Clopidogrel | Intervention Type: DRUG; Name: Aspirin monotherapy; Assigned to Arm(s): Aspirin | Intervention Type: DRUG; Name: Aspirin,Clopidogrel; Assigned to Arm(s): Aspirin,Clopidogrel
D: Arm Label: Prasugrel; Type: EXPERIMENTAL; Interventions: Drug: Prasugrel | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Prasugrel | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inhibition and Patient Outcomes]
Brief Summary: Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack. ACS is usually caused by the formation of a blood clot in an artery that partially or totally blocks the blood supply to a portion of the heart muscle. Ticagrelor will be compared with clopidogrel to determine which drug, when either is used in conjunction with aspirin, is better at reducing deaths from vascular causes, future heart attacks and/or strokes in patients with ACS.


Options:
A: Arm Label: Prasugrel; Type: EXPERIMENTAL; Interventions: Drug: Prasugrel | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Prasugrel | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: systematic coronary intervention | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Other: coronary intervention only for cases refractory to medical therapy | Intervention Type: OTHER; Name: systematic coronary intervention; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: coronary intervention only for cases refractory to medical therapy; Assigned to Arm(s): 2
C: Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Ticagrelor | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel
D: Arm Label: Radial; Type: EXPERIMENTAL; Interventions: Procedure: Radial approach | Arm Label: Femoral; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Femoral approach | Intervention Type: PROCEDURE; Name: Femoral approach; Assigned to Arm(s): Femoral | Intervention Type: PROCEDURE; Name: Radial approach; Assigned to Arm(s): Radial

Answer: C